Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from EFV/FTC/TDF to FTC/RPV/TAF in virologically suppressed adults with HIV-1
2014-004779-21Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of emtricitabine, rilpivirine, tenofovir alafenamide, efavirenz and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Virologic suppression at Week 48. Started Feb 2015; status: completed.
02
Drugs
emtricitabinerilpivirinetenofovir alafenamideefavirenztenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-004779-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004779-21.